Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ACS patients with intent for PCI \<72 hours from admission.~2. Prior clopidogrel loading within 24h before planned PCI or chronic (\>24 hours) treatment with clopidogrel~3. High platelet reactivity (HPR) PA \> 400 AU min by multiplate analyser (poor responders)~4. Initial platelet function sample at least 2 hours after pre PCI loading dose~5. Consent~Exclusion Criteria:~1. Patients \<18 years and \>75 years~2. Body weight \<60kg~3. Pretreatment with prasugrel within 7 days of randomisation~4. History of stroke or transient ischaemic attack~5. Patients with increased bleeding risk e.g.~   * recent major trauma or surgery~  * gastrointestinal bleeding or active peptic ulceration~  * Platelet count \<100,000 / mm3 at the time of screening~  * Internationally Normalized Ratio (INR)\> 1.5 at the time of screening~6. Hb\<10g/dL~7. Intracranial neoplasm, arteriovenous malformation or aneurysm.~8. Severe hepatic impairment (Child Pugh class C)~9. Intention to use the following medications~   * oral anticoagulation~  * other antiplatelet therapy (including GPIIb/IIIa inhibitors) besides aspirin~  * nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors~10. Female patients who are pregnant, planning pregnancy, not using reliable contraception or who are breastfeeding~11. Known allergy, hypersensitivity or other contraindications to prasugrel or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: ACTIVE_COMPARATOR): Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
- Clopidogrel (Type: ACTIVE_COMPARATOR): Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).